After many years of testing, the drug Pagoclone, believed to reduce stuttering in some people, is still not available for general use, and might never be. As reported by Tom Weidig on his blog, Endo Pharmaceuticals is closing the initial phase of testing according to their website, with no plans to put it on the market any time soon. They are starting a new phase of testing next year. As it stands, things do not look promising for development of a stuttering-reduction drug.

Gerald A. Maguire, MD, is an Associate Professor of Clinical Psychiatry, the Kirkup Chair in Stuttering, admitted during a talk at the National Stuttering Association conference in Cleveland, that the current testing phase was over.

More information on this subject will be posted on this site in the future.